Sphere Medical Holding plc (AIM: SPHR.L), (“Sphere Medical” or the “Company”) a leading provider of innovative monitoring and diagnostic devices for the critical care setting, is pleased to announce the appointment of Richard Wright as Chief Financial Officer. Richard will join the Company and the Board with effect from 10 August 2015.
From 2007 to 2015, Richard was Finance Director of Alliance Pharma plc, the UK based AIM-listed speciality pharmaceutical company. He is a Chartered Accountant with more than 20 years of experience in financial roles across a variety of sectors. Richard read Mathematics at Cambridge University and qualified as an accountant with Ernst & Young LLP.
Commenting on the appointment, Dr. Wolfgang Rencken, Chief Executive Officer of Sphere, said: "We are delighted to have attracted someone of Richard's calibre. His track record of managing Alliance Pharma through a strong commercial growth phase, as well as his extensive experience in negotiating and implementing numerous commercial deals, will strengthen our executive management team as we continue with the commercialisation of Proxima."
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Richard David Wright, aged 48 years, has been a director of the following companies during the five years preceding the date of this announcement:
Alliance Pharma plc
Alliance Pharmaceuticals Ltd
Alliance Pharmaceuticals GmbH (Germany)
Alliance Pharmaceuticals SAS (France)
Alliance Health Ltd
Opus Group Holdings Ltd
Opus Healthcare Ltd (UK)
Opus Healthcare Ltd (Ireland)
Macuvision Europe Ltd
Pursuant to the Company’s EMI Share Option Scheme, on 16 July 2015 1,340,000 share options were granted to Richard Wright at an exercise price of 17.75 pence each which are exercisable over ordinary shares of 1 pence each in the share capital of the Company. The exercise price of 17.75 pence equates to the closing mid market share price on 15 July 2015.
These share options are subject to vesting conditions and a minimum holding period of five years from grant. The issue of these share options has been approved by the Company's Remuneration Committee.
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Source credit: Sphere Medical